Preliminary safety results of the MITOBCG study in NMIBC скачать в хорошем качестве

Preliminary safety results of the MITOBCG study in NMIBC

Cosimo De Nunzio, MD, PhD, Sapienza University of Rome, Rome, Italy, shares an update on the preliminary findings of the Phase IV MITOBCG study (NCT03790384), which is investigating the safety and efficacy of sequential mitomycin and Bacillus Calmette-Guérin (BCG) versus BCG therapy alone for patients with high-risk non muscle-invasive bladder cancer (NMIBC). Dr De Nunzio talks on the initial safety findings, reporting that of 20 patients enrolled in the combination therapy arm so far, no significant differences in adverse effects have been observed in comparison to the BCG monotherapy arm, with three patients experiencing high-grade adverse events in each arm. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.